Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic maintains a 'Buy' rating on AngioDynamics (NASDAQ:ANGO) but lowers the price target from $20 to $17.
October 05, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target from $20 to $17, Canaccord Genuity maintains a 'Buy' rating on AngioDynamics.
The news is directly about AngioDynamics. The lowered price target might cause some investors to sell, but the maintained 'Buy' rating indicates that the analyst still sees potential in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100